Abstract:Streptococcus suis ( S. suis ) is an encapsulated zoonotic pathogen, which is responsible for bacterial meningitis and streptococcal toxic shock-like syndrome (STSLS). Despite many attempts to develop an effective vaccine, none is currently available. Here, a capsular polysaccharide (CPS)-expressing attenuated mutant 2015033 was constructed by deleting five virulence-associated factors ( sly , scpA , ssnA , fhb , and ssads ) in an outbreak S. suis strain SC19. Genes mentioned above are associated with either innate immunity-evading or tissue barrier-invading. Deletion of these genes did not impact the growth ability and CPS generation of 2015033, and the mutant exhibited no hemolytic activity to erythrocytes and no cytotoxicity to different epithelial or endothelial cells. In addition, 2015033 was more easily eliminated by whole human blood in vitro and by mouse blood in vivo . In addition, 2015033 showed a diminished invasive ability in different mouse organs (brain, lung, and liver) and avirulent properties in mice associated with weak inflammation-inducing ability. Immunization with 2015033 triggered T cell-dependent immunity and this immunity suppressed STSLS during SC19 infection by inhibiting excessive proinflammatory responses. In addition, immunization with 2015033 successfully conferred sequence type (STs)-independent protection to mice during heterogeneous infections (ST1, ST7, and ST658). This study presents the feasibility of the strategy of multi-gene deletion for the development of promising live vaccines against invasive encapsulated pathogens. IMPORTANCE S. suis is a traditional zoonotic agent causing human meningitis and STSLS, which is also a neglected emerging food-borne pathogen. Increasing antimicrobial resistance invokes reduction of preventative use of antibiotics in livestock creating an urgent need for effective vaccines. Given the expression of CPS is the basis for promising vaccines against encapsulated pathogens, and in order to find an effective and economical strategy for CPS-based vaccine development, multi-gene deletion was introduced into the design of a S. suis vaccine for the first time. From our results, CPS-expressing attenuated mutant 2015033 exhibited diminished evasive ability against the innate immune system and reduced invasive properties against different host barriers. To our knowledge, 2015033 is the first STSLS-suppressing S. suis vaccine to provide STs-independent protection during heterogeneous infections.

Intranasal Immunization with Multi-virulence Factors Promotes Mucosal Clearance of Streptococcus suis across Serotypes and Protects against Meningitis in Mice.

Immunogenicity and Cross-Protective Efficacy of Double-Mutant Streptococcus Suis ΔSspepO/ΔSspspC Serotypes 2 and 7.

Regulative synthesis of capsular polysaccharides in the pathogenesis of Streptococcus suis

A Streptococcus suis Strain Δcps/ssna-msly (P353L)-SC19 Provides Cross-Protection against Serotypes 2 and 9 Strain Challenges in a Mouse Model

TLR4 Agonist Combined with Trivalent Protein JointS of <i>Streptococcus suis</i> Provides Immunological Protection in Animals

Intracranial Subarachnoidal Route of Infection for Investigating Roles of Streptococcus Suis Biofilms in Meningitis in a Mouse Infection Model.

Combined Immunoinformatics to Design and Evaluate a Multi-Epitope Vaccine Candidate against Streptococcus suis Infection

Immunogenicity and Protective Capacity of EF-Tu and FtsZ of Streptococcus Suis Serotype 2 Against Lethal Infection.

Immunogenicity and Protective Capacity of Sugar ABC Transporter Substrate-Binding Protein against Streptococcus suis Serotype 2, 7 and 9 Infection in Mice

Insight into the role of Streptococcus suis zinc metalloprotease C from the new serotype causing meningitis in piglets

A multi-epitope subunit vaccine providing broad cross-protection against diverse serotypes of Streptococcus suis

Evaluation of the immunogenicity and protective ability of a pili subunit, SBP2', of Streptococcus suis serotype 2

Evaluation of the Protective Efficacy of Four Novel Identified Membrane Associated Proteins of Streptococcus Suis Serotype 2.

A capsular polysaccharide-expressing live vaccine suppresses streptococcal toxic shock-like syndrome and provides sequence type-independent protection during Streptococcus suis infection

Development of a Universal Multi-Epitope Vaccine Candidate Against Streptococcus Suis Infections Using Immunoinformatics Approaches

First Insights into the Protective Effects of a Recombinant Swinepox Virus Expressing Truncated MRP of Streptococcus Suis Type 2 in Mice.

A protein-based subunit vaccine with biological adjuvants provides effective protection against Pasteurella multocida in pigs

Progress Toward the Development of a Vaccine Against Streptococcus suis Capsular Type 2

A <i>Streptococcus suis</i> Strain Δ<i>cps/ssna</i>-m<i>sly</i> (P353L)-SC19 Provides Cross-Protection against Serotypes 2 and 9 Strain Challenges in a Mouse Model

Enhanced Systemic and Mucosal Immune Responses to Haemophilus parasuis by Intranasal Administration of Lactic-Co-Glycolic Acid Microspheres

A Streptococcus Suis Live Vaccine Suppresses Streptococcal Toxic Shock-Like Syndrome and Provides Sequence Type-Independent Protection.